LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

29.88 -2.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.4

Max

30.11

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -67M
Pelno marža	-7,753.425
Darbuotojai	186
EBITDA	-9.8M -73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+86.11% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	111M 1.6B
Ankstesnė atidarymo kaina	32.26
Ankstesnė uždarymo kaina	29.88

Naujienos nuotaikos

By Acuity

50%

139 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-27 23:53; UTC

Karštos akcijos

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026-02-27 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026-02-28 21:36; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 15:20; UTC

Uždarbis

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

2026-02-28 14:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 14:40; UTC

Svarbiausios naujienos

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

2026-02-28 14:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

2026-02-28 13:51; UTC

Svarbiausios naujienos

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

2026-02-28 13:47; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 13:44; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

2026-02-28 13:14; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 12:41; UTC

Svarbiausios naujienos

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

2026-02-28 02:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

2026-02-28 02:00; UTC

Įsigijimai, susijungimai, perėmimai

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

2026-02-28 02:00; UTC

Įsigijimai, susijungimai, perėmimai

Six Months, 9 Offers and $81 Billion. How -2-

2026-02-28 00:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

2026-02-27 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026-02-27 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026-02-27 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 21:30; UTC

Uždarbis

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026-02-27 21:30; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026-02-27 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026-02-27 21:17; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026-02-27 21:09; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026-02-27 21:00; UTC

Uždarbis

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026-02-27 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026-02-27 20:24; UTC

Rinkos pokalbiai

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026-02-27 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

86.11% į viršų

12 mėnesių prognozė

Vidutinis 56 USD 86.11%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

139 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.